adebrelimab + anlotinib

Adebrelimab + anlotinib is a combination therapy comprising a programmed cell death ligand 1 (PD-L1) inhibitor and a multi-target tyrosine kinase inhibitor (TKI). Adebrelimab (SHR-1316), developed by Jiangsu Hengrui Pharmaceuticals, is a humanized IgG4 monoclonal antibody that blocks the interaction between PD-L1 and its receptors (PD-1 and B7.1), thereby enhancing T-cell mediated immune responses against tumor cells. Anlotinib (AL3818), developed by Chia Tai Tianqing, is an oral small molecule that inhibits multiple receptor tyrosine kinases involved in angiogenesis and tumor proliferation, including VEGFR1-3, FGFR1-4, PDGFRα/β, and c-Kit. This combination is primarily being investigated for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with clinical research often led by institutions such as Shanghai Pulmonary Hospital. The rationale for the combination lies in the potential synergistic effects of anti-angiogenic therapy in modulating the tumor microenvironment to enhance the efficacy of immune checkpoint inhibitors.

Brand names

AdelyFukanghua

Other names

SHR-1316 + AL3818